ICMR launches a new vaccine portal for Covid, with details of trials

The portal covers other ailments as well; will provide details of progress made locally and globally at regular intervals

covid-19, vaccine, coronavirus
Serum Institute of India is conducting the India trials for the coronavirus vaccine developed by Oxford-AstraZeneca - Covishield
Ruchika Chitravanshi New Delhi
2 min read Last Updated : Sep 28 2020 | 11:56 PM IST
The Indian Council of Medical Research (ICMR) on Monday launched a vaccine and clinical registry portal to provide information on Covid-19 and other vaccines.

The portal, inaugurated by health and family welfare minister Harsh Vardhan, is a repository of information on development of vaccines and ongoing clinical trials, and will offer details of progress made locally and globally at regular intervals. 

The website has the details of animal trials, which have been conducted through various coronavirus vaccines currently under development, genome sequences of the virus along with academic papers on India’s vaccine preparedness.

A paper on the website, “Revisiting regulatory framework in India for accelerated vaccine development in pandemics with an evidence-based fast-tracking strategy”, published in the Indian Journal of Medical Research, talks of various phases of the emergency use authorisation of a Covid vaccine in the country. 

The portal is expected to be updated as more data on various vaccines becomes available.


As of now three vaccine candidates are the frontrunners in India: Zydus Cadila, Bharat Biotech and Serum Institute for Oxford-AstraZeneca vaccine.

Serum Institute of India is conducting the India trials for the coronavirus vaccine developed by Oxford-AstraZeneca, Covishield.

The company has entered phase three of the trials of the vaccine. Zydus Cadila and Bharat Biotech have completed the recruitments for phase two trial. Phase two human clinical trials for Bharat Biotech’s Covaxin and Zydus Cadila’s ZyCoV-D are ongoing, according to information on the vaccine portal.

India has used the Electronic Vaccine Intelligence Network (eVIN) to track information on vaccine supply chain and stocks across the country during the Covid-19 pandemic. This was done to ensure smooth immunisation across the country. This system provides real-time information on stocks and storage temperatures across registered vaccine storage sites in India.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusContact TracingContainment ZoneCommunity TransmissionLockdownCoronavirus VaccineCoronavirus TestsVaccineICMRSerum Institute of IndiaAstraZenecaBharat Biotech

Next Story